Allogene Historical Income Statement
| ALLO Stock | USD 1.89 0.18 8.70% |
Historical analysis of Allogene Therapeutics income statement accounts such as Selling General Administrative of 61.1 M, Total Revenue of 90.2 K or Research Development of 213.8 M can show how well Allogene Therapeutics performed in making a profits. Evaluating Allogene Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Allogene Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Allogene Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Allogene Therapeutics is a good buy for the upcoming year.
Allogene |
About Allogene Income Statement Analysis
Allogene Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Allogene Therapeutics shareholders. The income statement also shows Allogene investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Allogene Therapeutics Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most accounts from Allogene Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.At this time, Allogene Therapeutics' Interest Expense is very stable compared to the past year. As of the 18th of December 2024, Cost Of Revenue is likely to grow to about 255.1 M, while Selling General Administrative is likely to drop about 61.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 1.7M | 4.6M | 14.8M | 15.5M | Net Interest Income | 1.7M | 4.6M | 14.8M | 9.2M |
Allogene Therapeutics income statement Correlations
Click cells to compare fundamentals
Allogene Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Allogene Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 5.0M | 9.2M | 10.5M | 17.1M | 19.7M | 20.7M | |
| Selling General Administrative | 57.5M | 65.3M | 74.1M | 79.3M | 71.7M | 61.1M | |
| Gross Profit | (5.0M) | (11.5M) | 38.5M | 243K | (242.8M) | (230.7M) | |
| Operating Income | (202.0M) | (258.2M) | (255.8M) | (335.4M) | (327.7M) | (344.1M) | |
| Net Income From Continuing Ops | (184.6M) | (250.2M) | (257.0M) | (332.6M) | (332.9M) | (349.5M) | |
| Ebit | (202.0M) | (258.2M) | (255.8M) | (335.4M) | (314.5M) | (330.2M) | |
| Research Development | 144.5M | 193.0M | 220.2M | 256.4M | 242.9M | 213.8M | |
| Cost Of Revenue | 5.0M | 11.5M | 13.1M | 16.7M | 242.9M | 255.1M | |
| Total Operating Expenses | 202.0M | 258.2M | 294.3M | 335.7M | 327.8M | 253.1M | |
| Income Before Tax | (184.9M) | (250.2M) | (257.0M) | (332.6M) | (327.3M) | (343.6M) | |
| Total Other Income Expense Net | 17.1M | 8.0M | (1.2M) | 2.8M | 472K | 938.1K | |
| Net Income Applicable To Common Shares | (184.6M) | (250.2M) | (257.0M) | (332.6M) | (299.4M) | (314.3M) | |
| Net Income | (184.6M) | (233.5M) | (244.8M) | (329.8M) | (327.3M) | (343.6M) | |
| Income Tax Expense | (331K) | (16.8M) | (12.2M) | (2.8M) | (2.5M) | (2.7M) | |
| Net Interest Income | 17.4M | 9.2M | 1.7M | 4.6M | 14.8M | 9.2M | |
| Interest Income | 17.4M | 9.2M | 1.7M | 4.6M | 14.8M | 15.5M | |
| Depreciation And Amortization | 17.1M | 7.6M | 10.5M | 14.3M | 14.2M | 11.9M | |
| Other Operating Expenses | 202.0M | 258.2M | 294.3M | 335.7M | 327.8M | 295.3M | |
| Ebitda | (184.9M) | (250.7M) | (245.3M) | (321.2M) | (300.3M) | (315.3M) | |
| Reconciled Depreciation | 5.0M | 7.6M | 10.5M | 14.3M | 13.8M | 9.7M |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.66 | DYAI | Dyadic International | PairCorr |
| 0.52 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.51 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.